Table 3 Cost-effectiveness results at 10-year follow-up
Comparators | Cost | Effectiveness | ICER | |
|---|---|---|---|---|
MD | QALYs | |||
Episodic migraine | ||||
 Topiramate + BSC | €17,059 | 1,049 | 5.8839 | - |
 Erenumab + BSC | €21,479 | 877 | 6.1150 | €26/MD avoided |
€19,122/QALY gained | ||||
Chronic migraine | ||||
 Placebo + BSC | €24,921 | 2,100 | 4.5016 | - |
 Erenumab + BSC | €26,734 | 1,532 | 5.2578 | €3/MMD avoided |
€2,398/QALY gained | ||||